BioSpace News Archive

Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway.

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, announced updates resulting from rapidly changing market conditions driven by the novel coronavirus pandemic.

Novartis announced today, that in response to the COVID-19 pandemic in the US, Novartis and the Novartis US Foundation have established a US COVID-19 Community Response Fund.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that due to the emerging public health impact of the coronavirus outbreak (COVID-19), to support the health and well-being of our employees and stockholders, and to comply with the State of California’s stay at home order, its Board of Directors has approved a change in the location of its 2020 Annual Meeting of Stockholders

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 13 new employees.

Aperiomics, a biotechnology company deploying advanced technologies to identify the root causes of infectious disease, announced today that it expects to more than double its COVID-19 PCR testing capacity thanks to critical support from the Howard Hughes Medical Institute’s Janelia Research Campus, located in Ashburn, Virginia

Stryker, one of the world’s leading medical technology companies, announced today it has developed a low-cost, limited-release emergency response bed to quickly aid healthcare providers with efficient care during the COVID-19 pandemic.

In a letter sent to the leading trade organizations representing the nation’s hospitals and health systems, the National Kidney Foundation (NKF) expressed concern over news reports that some health systems and state governments are considering crisis-management policies which would deprive certain patient groups—including patients with end stage renal disease—of life-saving interventions for COVID-19

Stimwave Technologies, Inc., a global medical device company that provides minimally invasive, MRI-compatible battery-free implantable devices to treat chronic pain, today announced that Aure Bruneau has been named Chief Executive Officer, succeeding Paul LaViolette, effective immediately.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Food and Drug Administration (“FDA”) regarding SB206 for the treatment of molluscum.